JP6258943B2 - Ｈｍｂおよびａｔｐの組成物ならびに使用方法 - Google Patents

Ｈｍｂおよびａｔｐの組成物ならびに使用方法 Download PDF

Info

Publication number
JP6258943B2
JP6258943B2 JP2015531321A JP2015531321A JP6258943B2 JP 6258943 B2 JP6258943 B2 JP 6258943B2 JP 2015531321 A JP2015531321 A JP 2015531321A JP 2015531321 A JP2015531321 A JP 2015531321A JP 6258943 B2 JP6258943 B2 JP 6258943B2
Authority
JP
Japan
Prior art keywords
hmb
atp
muscle
strength
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015531321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527408A (ja
JP2015527408A5 (https=
Inventor
ベイアー，ショーン
コルブ，ラリー
ラスメイチャー，ジョン
Original Assignee
メタボリック・テクノロジーズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メタボリック・テクノロジーズ，インコーポレーテッド filed Critical メタボリック・テクノロジーズ，インコーポレーテッド
Publication of JP2015527408A publication Critical patent/JP2015527408A/ja
Publication of JP2015527408A5 publication Critical patent/JP2015527408A5/ja
Application granted granted Critical
Publication of JP6258943B2 publication Critical patent/JP6258943B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015531321A 2012-09-10 2013-09-10 Ｈｍｂおよびａｔｐの組成物ならびに使用方法 Active JP6258943B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698919P 2012-09-10 2012-09-10
US61/698,919 2012-09-10
PCT/US2013/059039 WO2014040067A1 (en) 2012-09-10 2013-09-10 Composition of hmb and atp and methods of use

Publications (3)

Publication Number Publication Date
JP2015527408A JP2015527408A (ja) 2015-09-17
JP2015527408A5 JP2015527408A5 (https=) 2016-11-04
JP6258943B2 true JP6258943B2 (ja) 2018-01-10

Family

ID=50237697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015531321A Active JP6258943B2 (ja) 2012-09-10 2013-09-10 Ｈｍｂおよびａｔｐの組成物ならびに使用方法

Country Status (14)

Country Link
US (1) US10092590B2 (https=)
EP (2) EP2892522A4 (https=)
JP (1) JP6258943B2 (https=)
CN (1) CN105025891B (https=)
AU (1) AU2013312113B2 (https=)
BR (1) BR112015005199B1 (https=)
CA (1) CA2884405C (https=)
DK (1) DK3733171T3 (https=)
ES (1) ES2970283T3 (https=)
FI (1) FI3733171T3 (https=)
HU (1) HUE065064T2 (https=)
PL (1) PL3733171T3 (https=)
PT (1) PT3733171T (https=)
WO (1) WO2014040067A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121177244A (zh) * 2016-05-25 2025-12-23 技源集团股份有限公司 包含3-羟基-3-甲基丁酸的软凝胶胶囊剂
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
WO2022271813A1 (en) * 2021-06-22 2022-12-29 Tsi Usa, Llc Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028440A (en) 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
FI951218A0 (fi) 1992-09-16 1995-03-15 Univ Iowa State Res Found Inc Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikolestrolin pitoisuuksien pienentämiseksi veressä
US5348979A (en) 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
JP4010390B2 (ja) 1999-09-20 2007-11-21 明治乳業株式会社 免疫賦活化組成物
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050027005A1 (en) 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2006034586A1 (en) 2004-09-29 2006-04-06 Aplodan Formulations Ltd. Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker
US20060073891A1 (en) * 2004-10-01 2006-04-06 Holt Timothy M Display with multiple user privacy
CN101184496A (zh) 2005-05-27 2008-05-21 兴和株式会社 用于恢复疲劳的药品
WO2007108071A1 (ja) 2006-03-17 2007-09-27 Pharma Foods International Co., Ltd. 抗ストレス組成物及びそれを含有する飲食品
CA2746420C (en) 2008-12-09 2019-11-12 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
DE102009052640A1 (de) 2009-11-10 2011-05-12 Linde-Lkca-Dresden Gmbh Verfahren und Vorrichtung zur Gaswäsche
DK2512236T3 (en) * 2009-12-18 2017-01-16 Metabolic Tech Inc IMPROVED PROCEDURE FOR ADMINISTRATION OF BETA-HYDROXY-BETA-METHYL BUTYRATE (HMB)

Also Published As

Publication number Publication date
FI3733171T3 (fi) 2024-01-24
JP2015527408A (ja) 2015-09-17
DK3733171T3 (da) 2024-01-29
EP3733171B1 (en) 2023-10-25
HK1217087A1 (zh) 2016-12-23
WO2014040067A1 (en) 2014-03-13
US20140080781A1 (en) 2014-03-20
EP2892522A4 (en) 2016-01-20
EP3733171A1 (en) 2020-11-04
US10092590B2 (en) 2018-10-09
HUE065064T2 (hu) 2024-05-28
EP2892522A1 (en) 2015-07-15
CA2884405C (en) 2021-03-30
BR112015005199A2 (pt) 2017-07-04
PT3733171T (pt) 2024-01-31
BR112015005199B1 (pt) 2022-09-06
AU2013312113B2 (en) 2018-08-02
CN105025891A (zh) 2015-11-04
CA2884405A1 (en) 2014-03-13
PL3733171T3 (pl) 2024-03-18
CN105025891B (zh) 2020-01-21
ES2970283T3 (es) 2024-05-27
AU2013312113A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
EP2512236B1 (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
JP5545424B2 (ja) 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
JP5762396B2 (ja) 糖尿病療法の支援のためのα−ケト酸を含有する栄養補助剤
EP3445355A1 (en) Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US20160303176A1 (en) Nutritional supplement
JP6258943B2 (ja) Ｈｍｂおよびａｔｐの組成物ならびに使用方法
CA2900526C (en) Compositions and their use to treat heart failure with preserved injection fraction (hfpef)
US10888576B2 (en) Composition of HMB and ATP and methods of use
McDonough Oral creatine hydrochloride supplementation: acute effects on submaximal, intermittent bouts of bench press and vertical jump exercises
US20160184248A1 (en) Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
HK1217087B (zh) Hmb和atp的组合物及使用方法
KR20230124538A (ko) 운동 없이 근육량, 근력 및 근육 기능을 개선하기 위한 β-하이드록시-β-메틸부티레이트(HMB)의 조성물 및 사용 방법
Demaison et al. Is there an ‘obesity paradox’of cardiac survival in heart disease? A perspective from experimental laboratory studies
Osowska Citrulline in health and disease. Review on human studies
Boyle Effects of Chronic Ingestion of L-arginine alpha ketoglutarate Combined With Creatine monohydrate on Anaerobic Performance in Strength-Trained Athletes
Del Favero Protein Turnover in Trained Male Endurance Runners Following Exercise
Rossouw Safety and effect of creatine monohydrate supplementation
Phillips Resistance Exercise Training: The Effects on Muscle Function, Body Composition and Risk Factors for Chronic Disease with Ageing
HK1170632A (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
HK1170632B (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171207

R150 Certificate of patent or registration of utility model

Ref document number: 6258943

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250